Table 1 . Enzyme elevation according to gender, coexisting medical problems and hepatotoxic drug consumption.
| Group with hepatotoxicity (%) | Group with non-hepatotoxicity (%) | p -value | |
| Gender (female) | 25 | 16.2 | 0.89 |
| Liver disease* | 50 | 22.7 | 0.09 |
| Congestive heart failure | 41.7 | 22.7 | 0.16 |
| Alcohol consumption | 1.8 | 0.5 | 0.42 |
| Cigarette smoking | 12.5 | 24.4 | 0.38 |
| Diabetes mellitus | 30.4 | 23 | 0.44 |
| Hypertriglyceridemia | 26.8 | 23 | 0.69 |
| Hypercholesterolemia | 32.3 | 22.4 | 0.44 |
| Hepatotoxic drug consumption** | 31.3 | 14 | 0.001 |
| Use of chloroquine | 22.8 | 26.9 | 0.69 |
* Autoimmune hepatitis, non-alcoholic steatohepatitis, liver congestion due to congestive heart failure and mitral stenosis, Gilberts’ disease, autoimmune hepatitis and liver hemangioma.
** NSAID, Sulfasalazine, Angiotensin Converting Enzyme inhibitors and Angiotensin Receptor Blockers, Statins and Omeprazole. (Prednisolone has been used in all of the patients).